Posting of Report & Accounts and Notice of Meeting

RNS Number : 9283H

AorTech International PLC

05 August 2019

 

5 August 2019

AorTech International plc

("AorTech", the "Company" or the "Group")

Posting of Report & Accounts

and

Notice of Meeting

 AorTech International plc (AIM: AOR), the biomaterials IP and medical device development company, announces that its Annual Report and Accounts for the year ended 31 March 2019, have been posted to shareholders and are available on the Company's website at https://www.aortech.net/wp-content/uploads/2019/07/Aortech-Annual-Report-July-2019.pdf.

The Annual General Meeting will be held on Monday 19 August 2019 at 11.00 a.m. at the offices of Davidson Chalmers Stewart LLP at 163 Bath Street Glasgow G2 4SQ.

For further information contact:

AorTech International plc                                                            Tel: [phone]

Bill Brown, Executive Chairman                                                   

Shore Capital                                                                                 Tel: [phone]

Tom Griffiths / David Coaten                                                      

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on its behalf by Biomerics LLC in Utah, USA. Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 6 million implants and over 10 years of successful clinical use AorTech polymers are proven in long term life enabling applications.

In addition to continuing to exploit AorTech's Intellectual Property related to the world class biomaterial -

Elast-Eon™, AorTech is now incorporating this material into a number of medical devices of our own design. Elast-Eon™ has first class long term blood contacting properties and as a result, all of the initial products being developed are for the cardio vascular field. Each device is being designed to have improved clinical outcomes over current device technology,eliminating the use of animal sourced material whilst allowing procedures to remain the same, therefore avoiding the need of having to retrain surgeons in new ways of operating.

 

END

 

 

ACSFMGGRZKZGLZM